Recently, a monoclonal antibody therapy targeting C-C chemokine receptor type 4 (CCR4), which is expressed on HTLV-1–infected cells, was used in a clinical trial with patients with HAM/TSP, showing a reduction in infected cells (35). Here, CCR4 is linked to tropical spastic paraparesis.